Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 261

1.

Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients.

Kuypers DR, Ekberg H, Grinyó J, Nashan B, Vincenti F, Snell P, Mamelok RD, Bouw RM.

Clin Pharmacokinet. 2009;48(5):329-41. doi: 10.2165/00003088-200948050-00005.

PMID:
19566116
2.

Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.

Musuamba FT, Rousseau A, Bosmans JL, Senessael JJ, Cumps J, Marquet P, Wallemacq P, Verbeeck RK.

Clin Pharmacokinet. 2009;48(11):745-58. doi: 10.2165/11318060-000000000-00000.

PMID:
19817503
3.

Clinical pharmacokinetics of mycophenolate mofetil.

Bullingham RE, Nicholls AJ, Kamm BR.

Clin Pharmacokinet. 1998 Jun;34(6):429-55. Review.

PMID:
9646007
4.

Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.

Staatz CE, Tett SE.

Clin Pharmacokinet. 2007;46(1):13-58. Review.

PMID:
17201457
5.

Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.

de Winter BC, van Gelder T, Sombogaard F, Shaw LM, van Hest RM, Mathot RA.

J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):541-64. doi: 10.1007/s10928-009-9136-6. Epub 2009 Nov 11.

6.

Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report.

Shipkova M, Armstrong VW, Kuypers D, Perner F, Fabrizi V, Holzer H, Wieland E, Oellerich M; MMF Creeping Creatinine Study Group.

Ther Drug Monit. 2001 Dec;23(6):717-21.

PMID:
11802109
8.

Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.

Tett SE, Saint-Marcoux F, Staatz CE, Brunet M, Vinks AA, Miura M, Marquet P, Kuypers DR, van Gelder T, Cattaneo D.

Transplant Rev (Orlando). 2011 Apr;25(2):47-57. doi: 10.1016/j.trre.2010.06.001. Epub 2010 Dec 28.

PMID:
21190834
9.

Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.

Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B.

J Clin Pharm Ther. 2006 Feb;31(1):27-34.

PMID:
16476117
10.
12.

Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.

Beckebaum S, Armstrong VW, Cicinnati VR, Streit F, Klein CG, Gerken G, Paul A, Oellerich M.

Ther Drug Monit. 2009 Apr;31(2):205-10. doi: 10.1097/FTD.0b013e31819743d9.

PMID:
19307937
13.

Trough levels of mycophenolic acid and its glucuronidated metabolite in renal transplant recipients.

Merkel U, Lindner S, Vollandt R, Sperschneider H, Balogh A.

Int J Clin Pharmacol Ther. 2005 Aug;43(8):379-88.

PMID:
16119513
14.

The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy.

Grinyó JM, Ekberg H, Mamelok RD, Oppenheimer F, Sánchez-Plumed J, Gentil MA, Hernandez D, Kuypers DR, Brunet M.

Nephrol Dial Transplant. 2009 Jul;24(7):2269-76. doi: 10.1093/ndt/gfp162. Epub 2009 Apr 8.

PMID:
19357111
15.

Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients.

Naesens M, Kuypers DR, Streit F, Armstrong VW, Oellerich M, Verbeke K, Vanrenterghem Y.

Clin Pharmacol Ther. 2006 Nov;80(5):509-21.

PMID:
17112807
16.

Effects of calcineurin inhibitors on pharmacokinetics of mycophenolic acid and its glucuronide metabolite during the maintenance period following renal transplantation.

Naito T, Shinno K, Maeda T, Kagawa Y, Hashimoto H, Otsuka A, Takayama T, Ushiyama T, Suzuki K, Ozono S.

Biol Pharm Bull. 2006 Feb;29(2):275-80.

17.
18.

Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.

Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J.

Transpl Immunol. 1997 Sep;5(3):225-32.

PMID:
9402690
19.

A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, Hené RJ, Verpooten GA, Navarro MT, Hale MD, Nicholls AJ.

Transplantation. 1999 Jul 27;68(2):261-6.

PMID:
10440399
20.

Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.

Cremers S, Schoemaker R, Scholten E, den Hartigh J, König-Quartel J, van Kan E, Paul L, de Fijter J.

Br J Clin Pharmacol. 2005 Sep;60(3):249-56.

Supplemental Content

Support Center